A review published in
Genes & Diseases highlights how the machinery that tags and manages proteins could offer new directions for treating
cardiovascular disease. Researchers at the Affiliated Hospital of Zunyi Medical University examine the
ubiquitin system and its influence on heart muscle injury, blood vessel inflammation, abnormal heart rhythms, and hypertension.
Ubiquitination involves attaching a protein called ubiquitin to other proteins. These tags can mark damaged or unwanted proteins for destruction, but they also regulate signalling and cellular activity. Enzymes called
E3 ubiquitin ligases help select which proteins receive the tags, while
deubiquitinating enzymes can remove them, creating a reversible control system.
The review brings together evidence across
atherosclerosis, injury associated with restoring blood flow after cardiac ischemia, cardiac remodelling, arrhythmias, and high blood pressure. It explains how disrupted protein regulation can alter heart cell survival, activate scar-forming fibroblasts, and change the behaviour of immune cells and vascular smooth muscle cells.
One finding is that ubiquitination can either protect cardiovascular tissues or contribute to disease. Removing harmful proteins may reduce injury, whereas degrading protective proteins can intensify inflammation or impair heart function. The effects depend on the enzyme involved, its protein targets, the cell type, and the timing of intervention.
In experimental studies discussed in the review, the enzyme
USP25 helped preserve
SERCA2a, a protein important for calcium handling in heart cells. This stabilisation reduced pathological heart muscle enlargement in animal models, illustrating how selective manipulation of protein turnover could support cardiac protection.
The article also examines connections between ubiquitination and other protein modifications, including phosphorylation and acetylation. These interacting processes shape stress responses, mitochondrial quality control, inflammation, and fibrosis. Understanding their coordination could help researchers identify precise treatment targets.
Potential strategies include selective enzyme modulators and
targeted protein degradation technologies such as
PROTACs and
molecular glues. These approaches aim to influence particular proteins rather than broadly disrupting cellular protein management. Their cardiovascular applications still require tissue-specific delivery and validation in humans.
Safety remains a consideration. Broad proteasome inhibitors used in cancer treatment have caused clinically significant heart toxicity, demonstrating the risks of interfering with a system essential to normal cellular function. Overlapping enzyme activities and shared protein targets also complicate drug development.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Diseases may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)
# # # # # #
Reference
Jingjing Zhu, Zhimei Qiu, Yi Xu, Qing Guo, Shuangya Yang, Yongchao Zhao, Bei Shi, The ubiquitin system in heart and vessel pathobiology: From mechanisms to therapeutic strategies, Genes & Diseases, Volume 13, Issue 6, 2026, 102023,
https://doi.org/10.1016/j.gendis.2025.102023
Funding
National Natural Science Foundation of China
82470291
National Natural Science Foundation of China
82460055